Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 55/100

Failure Rate

18.2%

6 terminated/withdrawn out of 33 trials

Success Rate

64.7%

-21.8% vs industry average

Late-Stage Pipeline

36%

12 trials in Phase 3/4

Results Transparency

18%

2 of 11 completed trials have results

Key Signals

4 recruiting2 with results6 terminated

Enrollment Performance

Analytics

Phase 2

13(44.8%)

Phase 3

11(37.9%)

Phase 1

4(13.8%)

Phase 4

1(3.4%)

29Total

Phase 2(13)

Phase 3(11)

Phase 1(4)

Phase 4(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (33)

Showing 20 of 33 trials

NCT07554495Phase 3Not Yet Recruiting

Safety, Tolerability, Pharmacokinetics, and Efficacy of Filgotinib for the Treatment of Polyarticular-course Juvenile Idiopathic Arthritis in Children and Adolescents

Role: lead

NCT07553182Phase 3Recruiting

OLE Study With Filgotinib in JIA

Role: lead

NCT06865417Phase 3Recruiting

A Study Evaluating the Effects of Filgotinib in Children and Teenagers With Ulcerative Colitis

Role: lead

NCT07363980Enrolling By Invitation

Coronary Computed Tomography Angiography In Rheumatoid Arthritis Study

Role: collaborator

NCT05817942Active Not Recruiting

Prospective Observational Study of Effectiveness and Safety of Filgotinib in Participants With Ulcerative Colitis (UC)

Role: lead

NCT06222034Phase 1Recruiting

Study to Measure Filgotinib in the Blood of Children and Teenagers With Arthritis Taking Filgotinib (SCALESIA)

Role: lead

NCT05323591Active Not Recruiting

Prospective Observational Study of Filgotinib in Participants With Rheumatoid Arthritis in France

Role: lead

NCT05785611Phase 3Active Not Recruiting

A Study Evaluating the Effect of Filgotinib in Participants With Active Axial Spondyloarthritis

Role: lead

NCT04871919Active Not Recruiting

Prospective Observational Study of Filgotinib in Subjects With Rheumatoid Arthritis

Role: lead

NCT05724069Phase 2Completed

Velusetrag for the Treatment of Chronic Intestinal Pseudo-Obstruction (CIPO).

Role: lead

NCT01467726Phase 1Completed

Safety, Pharmacokinetics and Pharmacodynamics of Velusetrag in Healthy Elderly Subjects

Role: lead

NCT00391820Phase 2Completed

Evaluate the Safety and Efficacy of a 5-HT4 Agonist in Chronic Constipation (ACCORD Trial)

Role: lead

NCT03025308Phase 3Completed

Long Term Extension Study to Assess the Safety and Efficacy of Filgotinib in Adults With Rheumatoid Arthritis

Role: lead

NCT03069131Phase 3Completed

Two Strategies of Primary Prophylaxis of Spontaneous Bacterial Peritonitis in Severe Cirrhotic Patients With Ascites

Role: collaborator

NCT02914535Phase 3Active Not Recruiting

Filgotinib in Long-Term Extension Study of Adults With Ulcerative Colitis

Role: lead

NCT05371925Phase 3Completed

Endothelial Protection in Post COVID-19 Patients With Sulodexide

Role: collaborator

NCT06285539Phase 2Recruiting

Drug Rediscovery for Rare Immune Mediated Inflammatory Diseases

Role: collaborator

NCT05150587Phase 2Completed

Safety, Efficacy and Pharmacokinetics of Rifaximin in Patients With Moderate-to-severe Papulopustular Rosacea

Role: lead

NCT05005052Phase 3Unknown

Sulodexide in the Treatment of Chronic Primary Venous Disease of the Lower Extremities

Role: collaborator

NCT03469050Phase 2Terminated

Rifaximin Delayed Release for the Prevention of Recurrent Acute Diverticulitis and Diverticular Complications.

Role: lead